Dr. John Hall
Vice President of Global Medical Affairs, Quintiles
Patients are emerging as an increasingly powerful voice in the conversations surrounding healthcare delivery and clinical research. As such, biopharmaceutical companies and paying organizations will increasingly need to realize the decision-making power of patients, take the time to understand patient needs, and communicate to patients both the value and risks of new pharmacologic treatments.
- Three-quarters of U.S. patients consider their health good to excellent, but only about half of U.K. patients offered a similar assessment.
- Seventy-two percent of U.S. patients and 81 percent of U.K. patients believe they should be able to choose to take potentially risky medication, even if it is not approved for use, if they feel it is their only chance to improve their health.
- More than nine-out-of-10 U.S. and U.K. patients feel adequately informed about the benefits of taking their medication, but both groups are less certain of the potential risks.
- Among all groups surveyed, patients are the least hopeful about the future of healthcare, with only 49 percent of U.S. patients and 38 percent of U.K. patients expressing optimism that the quality of healthcare will be improved 10 years from now.
Data for this survey were collected from 509 U.S. and 500 U.K. adults ages 18 and over diagnosed with a chronic health condition.